search
Back to results

Pea Protein and Muscle Mass During Weight Loss

Primary Purpose

Obesity

Status
Completed
Phase
Not Applicable
Locations
Canada
Study Type
Interventional
Intervention
Pea Protein
Whey Protein
Maltodextrin
Sponsored by
University of Manitoba
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Obesity

Eligibility Criteria

30 Years - 50 Years (Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  1. Male, or non-pregnant, non-lactating female, 30 to 50 years of age;
  2. BMI >30 and body weight does not exceed the capacity of the DEXA (350 lbs);
  3. Fat mass >23% for males and >32% for females (determined at the screening visit via bioelectrical impedance);
  4. Willing to maintain a stable level of activity while participating in the study;
  5. Plasma creatinine ≤265 µmol/L;
  6. Plasma LDL-cholesterol <5 mmol/L;
  7. Aspartate aminotransferase <160 U/L, and alanine aminotransferase <150 U/L;
  8. Glycated hemoglobin <6.5%;
  9. Blood pressure <160 mmHg systolic and <100 mmHg diastolic;
  10. Stable regime if taking vitamin and mineral/dietary/herbal supplements for the past 1 month and while participating in the study;
  11. Not taking protein supplements for the past month and willing to continue doing so for the duration of the study;
  12. Has not donated blood or blood products (e.g. platelets) during the past 2 months and willing to continue doing so while participating in the study;
  13. Female participants of child-bearing potential must agree to use a highly effective method of contraception throughout the study;
  14. Not participating in another dietary intervention trial for the past month and willing to not start another dietary intervention trial or weight loss program for the duration of this study;
  15. Willing to comply with the protocol requirements and procedures;
  16. Willing to provide informed consent.

Exclusion Criteria:

  1. Has experienced a cardiovascular event (e.g. heart attack, stroke) or had a surgical procedure for cardiovascular disease (e.g. bypass, stent), presence of diabetes, chronic renal disease, liver disease (with exception of fatty liver), rheumatoid arthritis, immune disorder or disease (e.g. multiple sclerosis, leukemia), cancer in the previous 5 years, neurological disorders, gastrointestinal disorders or gastrointestinal surgery or bariatric surgery, or liposuction;
  2. Taking medications for blood glucose management;
  3. Taking medications or natural health products/supplements associated with weight gain or weight loss (e.g. prednisone, certain cold medications);
  4. Body weight that has not been stable (± 5%) over the past 3 months;
  5. History of gastrointestinal reactions or allergies to peas, pea protein, whey protein or maltodextrin, or to one or more ingredients in the beverages and foods that will be provided which significantly limits the number of items that can be used for delivery of the protein powders or maltodextrin;
  6. Current (within the past 30 days) bacterial, viral or fungal infection;
  7. Uncontrolled hypothyroidism;
  8. Uncontrolled blood pressure;
  9. Bleeding disorder;
  10. Any acute medical condition or surgical intervention within the past 3 months;
  11. Cigarette/cigar smoking or use of tobacco products within the last 12 months or during participation in the study;
  12. Consumption of >10 alcoholic beverages per week or >2 alcoholic beverages per day within the last 3 months or while participating in the study;
  13. Drug and/or alcohol abuse;
  14. Psychological disorder(s);
  15. Unable to obtain blood sample at the screening or week 0 visits.

Sites / Locations

  • I.H Asper Clinical Research Institute, St. Boniface Hospital

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Experimental

Active Comparator

Placebo Comparator

Arm Label

Pea Protein

Whey Protein

Maltodextrin

Arm Description

Participants will consume pea protein (0.35 grams protein/kg body weight/day) as a powder incorporated into foods or beverages at least twice per day for 12 weeks.

Participants will consume whey protein (0.35 grams protein/kg body weight/day) as a powder incorporated into foods or beverages at least twice per day for 12 weeks.

Participants will consume maltodextrin (isocaloric non-protein comparator) as a powder incorporated into foods or beverages at least twice per day for 12 weeks.

Outcomes

Primary Outcome Measures

Change in muscle mass
Muscle mass will be assessed by dual x-ray absorptiometry
Change in muscle function (hand grip)
A dynamometer will be used to measure hand grip strength
Change in muscle function (gait test)
A gait test will be performed

Secondary Outcome Measures

Change in fat mass
Fat mass will be measured by dual x-ray absorptiometry
Change in body weight and body mass index
Body weight will be measured and used for calculation of body mass index
Change in waist and waist to height ratio
Waist circumferences will be measured and used for calculation of waist to height ratio
Change in resting energy expenditure
Resting energy expenditure will be measured by metabolic cart
Change in C-reactive protein
A fasting venous blood sample will be analyzed for C-reactive protein to assess inflammatory status
Change in homeostatic model for insulin resistance (HOMA-IR)
A fasting venous blood sample will be analyzed for insulin and glucose to calculate HOMA-IR using the formula fasting insulin x fasting glucose / 405
Change in glycated hemoglobin
A fasting venous blood sample will be analyzed for glycated hemoglobin
Change in blood lipid profile
A fasting venous blood sample will be analyzed for total cholesterol, LDL-cholesterol, HDL-cholesterol and triglycerides as the blood lipid profile
Change in kidney function (based on profile of circulating markers)
A fasting venous blood sample will be analyzed for blood urea nitrogen and serum creatinine to obtain a profile of circulating markers for assessing kidney function
Change in kidney function (based on profile of urinary markers)
A spot urine sample will be analyzed for urine albumin, creatinine and urea to obtain a profile of urinary markers for assessing kidney function
Change in liver function (based on profile of circulating markers)
A fasting venous blood sample will be analyzed for plasma alanine aminotransferase and aspartate aminotransferase to obtain a profile of circulating markers for assessing liver function
Change in systolic and diastolic blood pressure
Systolic and diastolic blood pressure will be measured
Changes in blood vessel function
Pulse wave velocity measurements will obtained for assessment of arterial stiffness, an indicator of blood vessel function
24 h activity patterns over time
Participants will wear a Fitbit to monitor 24 hour activity patterns
Food intake over time
Participants will complete 3-Day Food Records at 3 week intervals for analysis of nutrient intake

Full Information

First Posted
September 26, 2019
Last Updated
August 1, 2023
Sponsor
University of Manitoba
search

1. Study Identification

Unique Protocol Identification Number
NCT04123938
Brief Title
Pea Protein and Muscle Mass During Weight Loss
Official Title
A Pilot Study to Examine the Effect of Pea Protein on Limiting the Loss of Muscle Mass During Weight Loss
Study Type
Interventional

2. Study Status

Record Verification Date
August 2023
Overall Recruitment Status
Completed
Study Start Date
October 17, 2019 (Actual)
Primary Completion Date
May 2, 2023 (Actual)
Study Completion Date
May 2, 2023 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University of Manitoba

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
A pilot study comparing the effects of pea protein versus whey protein on the preservation of muscle mass and functionality in individuals undertaking a weight loss regimen.
Detailed Description
A single site, double-blind, randomized clinical trial designed to compare the effects of pea protein or whey protein or maltodextrin supplementation on muscle mass and functionality in males and females with obesity undertaking a weight loss regimen. Eligible participants will be randomized to one of the three groups (pea protein, whey protein, maltodextrin) and will be asked to attend 3 in-person clinic visits (0, 6, and 12 weeks) for blood and urine collection and assessments of muscle mass and muscle function. A separate visit for screening and for a fasting blood sample, as well as a Pre-Study visit and a meeting with a registered dietitian, will be required.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Obesity

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
60 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Pea Protein
Arm Type
Experimental
Arm Description
Participants will consume pea protein (0.35 grams protein/kg body weight/day) as a powder incorporated into foods or beverages at least twice per day for 12 weeks.
Arm Title
Whey Protein
Arm Type
Active Comparator
Arm Description
Participants will consume whey protein (0.35 grams protein/kg body weight/day) as a powder incorporated into foods or beverages at least twice per day for 12 weeks.
Arm Title
Maltodextrin
Arm Type
Placebo Comparator
Arm Description
Participants will consume maltodextrin (isocaloric non-protein comparator) as a powder incorporated into foods or beverages at least twice per day for 12 weeks.
Intervention Type
Other
Intervention Name(s)
Pea Protein
Other Intervention Name(s)
NUTRALYS S85
Intervention Description
Soluble pea protein
Intervention Type
Other
Intervention Name(s)
Whey Protein
Other Intervention Name(s)
Whey Protein Concentrate 80 Instant Kosher
Intervention Description
Whey protein concentrate
Intervention Type
Other
Intervention Name(s)
Maltodextrin
Other Intervention Name(s)
GLUCIDEX 19
Intervention Description
Non-protein isocaloric comparator
Primary Outcome Measure Information:
Title
Change in muscle mass
Description
Muscle mass will be assessed by dual x-ray absorptiometry
Time Frame
Baseline and 12 weeks
Title
Change in muscle function (hand grip)
Description
A dynamometer will be used to measure hand grip strength
Time Frame
Baseline and 12 weeks
Title
Change in muscle function (gait test)
Description
A gait test will be performed
Time Frame
Baseline and 12 weeks
Secondary Outcome Measure Information:
Title
Change in fat mass
Description
Fat mass will be measured by dual x-ray absorptiometry
Time Frame
Baseline and 12 weeks
Title
Change in body weight and body mass index
Description
Body weight will be measured and used for calculation of body mass index
Time Frame
Baseline and 12 weeks
Title
Change in waist and waist to height ratio
Description
Waist circumferences will be measured and used for calculation of waist to height ratio
Time Frame
Baseline and 12 weeks
Title
Change in resting energy expenditure
Description
Resting energy expenditure will be measured by metabolic cart
Time Frame
Baseline and 12 weeks
Title
Change in C-reactive protein
Description
A fasting venous blood sample will be analyzed for C-reactive protein to assess inflammatory status
Time Frame
Baseline and 12 weeks
Title
Change in homeostatic model for insulin resistance (HOMA-IR)
Description
A fasting venous blood sample will be analyzed for insulin and glucose to calculate HOMA-IR using the formula fasting insulin x fasting glucose / 405
Time Frame
Baseline and 12 weeks
Title
Change in glycated hemoglobin
Description
A fasting venous blood sample will be analyzed for glycated hemoglobin
Time Frame
Baseline and 12 weeks
Title
Change in blood lipid profile
Description
A fasting venous blood sample will be analyzed for total cholesterol, LDL-cholesterol, HDL-cholesterol and triglycerides as the blood lipid profile
Time Frame
Baseline and 12 weeks
Title
Change in kidney function (based on profile of circulating markers)
Description
A fasting venous blood sample will be analyzed for blood urea nitrogen and serum creatinine to obtain a profile of circulating markers for assessing kidney function
Time Frame
Baseline and 12 weeks
Title
Change in kidney function (based on profile of urinary markers)
Description
A spot urine sample will be analyzed for urine albumin, creatinine and urea to obtain a profile of urinary markers for assessing kidney function
Time Frame
Baseline and 12 weeks
Title
Change in liver function (based on profile of circulating markers)
Description
A fasting venous blood sample will be analyzed for plasma alanine aminotransferase and aspartate aminotransferase to obtain a profile of circulating markers for assessing liver function
Time Frame
Baseline and 12 weeks
Title
Change in systolic and diastolic blood pressure
Description
Systolic and diastolic blood pressure will be measured
Time Frame
Baseline and 12 weeks
Title
Changes in blood vessel function
Description
Pulse wave velocity measurements will obtained for assessment of arterial stiffness, an indicator of blood vessel function
Time Frame
Baseline and 12 weeks
Title
24 h activity patterns over time
Description
Participants will wear a Fitbit to monitor 24 hour activity patterns
Time Frame
Up to 12 weeks
Title
Food intake over time
Description
Participants will complete 3-Day Food Records at 3 week intervals for analysis of nutrient intake
Time Frame
Up to 12 weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
30 Years
Maximum Age & Unit of Time
50 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Male, or non-pregnant, non-lactating female, 30 to 50 years of age; BMI >30 and body weight does not exceed the capacity of the DEXA (350 lbs); Fat mass >23% for males and >32% for females (determined at the screening visit via bioelectrical impedance); Willing to maintain a stable level of activity while participating in the study; Plasma creatinine ≤265 µmol/L; Plasma LDL-cholesterol <5 mmol/L; Aspartate aminotransferase <160 U/L, and alanine aminotransferase <150 U/L; Glycated hemoglobin <6.5%; Blood pressure <160 mmHg systolic and <100 mmHg diastolic; Stable regime if taking vitamin and mineral/dietary/herbal supplements for the past 1 month and while participating in the study; Not taking protein supplements for the past month and willing to continue doing so for the duration of the study; Has not donated blood or blood products (e.g. platelets) during the past 2 months and willing to continue doing so while participating in the study; Female participants of child-bearing potential must agree to use a highly effective method of contraception throughout the study; Not participating in another dietary intervention trial for the past month and willing to not start another dietary intervention trial or weight loss program for the duration of this study; Willing to comply with the protocol requirements and procedures; Willing to provide informed consent. Exclusion Criteria: Has experienced a cardiovascular event (e.g. heart attack, stroke) or had a surgical procedure for cardiovascular disease (e.g. bypass, stent), presence of diabetes, chronic renal disease, liver disease (with exception of fatty liver), rheumatoid arthritis, immune disorder or disease (e.g. multiple sclerosis, leukemia), cancer in the previous 5 years, neurological disorders, gastrointestinal disorders or gastrointestinal surgery or bariatric surgery, or liposuction; Taking medications for blood glucose management; Taking medications or natural health products/supplements associated with weight gain or weight loss (e.g. prednisone, certain cold medications); Body weight that has not been stable (± 5%) over the past 3 months; History of gastrointestinal reactions or allergies to peas, pea protein, whey protein or maltodextrin, or to one or more ingredients in the beverages and foods that will be provided which significantly limits the number of items that can be used for delivery of the protein powders or maltodextrin; Current (within the past 30 days) bacterial, viral or fungal infection; Uncontrolled hypothyroidism; Uncontrolled blood pressure; Bleeding disorder; Any acute medical condition or surgical intervention within the past 3 months; Cigarette/cigar smoking or use of tobacco products within the last 12 months or during participation in the study; Consumption of >10 alcoholic beverages per week or >2 alcoholic beverages per day within the last 3 months or while participating in the study; Drug and/or alcohol abuse; Psychological disorder(s); Unable to obtain blood sample at the screening or week 0 visits.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Peter Zahradka, PhD
Organizational Affiliation
St. Boniface Hospital Albrechtsen Research Centre
Official's Role
Principal Investigator
Facility Information:
Facility Name
I.H Asper Clinical Research Institute, St. Boniface Hospital
City
Winnipeg
State/Province
Manitoba
ZIP/Postal Code
R2H 2A6
Country
Canada

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Pea Protein and Muscle Mass During Weight Loss

We'll reach out to this number within 24 hrs